Loading...
NPI 1295952596 · Elgin, IL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Veerpal Singh is a hematology & oncology physician provider located in Elgin, Illinois. This profile covers 67 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Veerpal Singh |
| Address | 1710 N Randall Rd |
| City | Elgin |
| State | IL |
| ZIP | 60123 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | April 19, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.4M |
| Medicaid | $67.3K |
This clinician is a Hematology & Oncology Physician with total Medicare revenue of $3.4M and a code mix dominated by high-cost oncology therapeutics and infusion services; the three highest-revenue Medicare codes (J9271, J9299, J0897) together account for 59.7% of Medicare revenue, which signals an operation centered on immunotherapy and bone-modifying agents delivered in an infusion setting. The presence of multiple chemotherapy administration and supportive-care drug codes confirms a practice that is treatment- and infusion-focused rather than purely office-based consults.
At the drug level, J9271 (pembrolizumab) produced $868.6K (26.6% of Medicare revenue) and ranks #383 of 1841 providers nationally (79th percentile; typical, unremarkable volume for this code), while J9299 (nivolumab) produced $774.7K (23.7%) and ranks #61 of 505 providers nationally (88th percentile; typical, unremarkable volume for this code). J0897 (denosumab) contributed $306.7K (9.4%) and ranks #409 of 10057 providers nationally (96th percentile; notably above typical national volume for this code), indicating particularly strong denosumab utilization relative to the broader national oncology cohort.
Procedure and infusion-service usage is pronounced: chemotherapy infusion code 96413 generated $92.4K (2.8% of Medicare revenue) and ranks #120 of 7514 providers nationally (98th percentile; extreme outlier, far above typical national volume for this code), and IV push/add-on infusion code 96375 produced $25.2K (0.8%) and ranks #31 of 5191 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). High-paid supportive agents and growth-factor administrations such as J2506 (pegfilgrastim) at $88.8K (2.7%, rank #28 of 586; 95th percentile; notably above typical national volume for this code) further reinforce that the practice operates a high-throughput infusion and supportive-care service line.
Revenue concentration poses business implications: the precomputed top-3 Medicare codes account for 59.7% of Medicare revenue, meaning a majority of Medicare cash flow is tied to a small set of immunotherapy and infusion drugs. That concentration creates sensitivity to changes in drug pricing, payer coverage, or utilization patterns for those specific agents.
Medicaid activity is almost entirely E/M-driven: total Medicaid revenue is $67.3K and the top three Medicaid codes (99214, 99232, 99233) account for 99.7% of Medicaid revenue, with 99214 at $37.8K (56.2%) and 99232 at $26.3K (39.1%). These Medicaid codes rank in-state as 99214 #2502 of 14681 (83th percentile; typical, unremarkable volume for this code), 99232 #1096 of 4799 (77th percentile; typical, unremarkable volume for this code), and 99233 #2219 of 3828 (42th percentile; typical, unremarkable volume for this code), indicating the provider’s Medicaid work is concentrated in routine outpatient and subsequent inpatient E/M visits rather than in high-cost drug administration.
The payer mix is heavily Medicare-dominant: Medicare revenue of $3.4M dwarfs Medicaid revenue of $67.3K, so the provider is effectively a Medicare-focused practice in scale and financial exposure. Any strategic or contractual change in Medicare reimbursement will materially affect overall revenue, while Medicaid represents a comparatively small share of billings.
The provider shows unusually high E/M billing intensity within Medicare: 99214 posted $167.3K (5.1% of Medicare revenue) and ranks #2133 of 479517 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), and 99213 posted $121.3K (3.7%) and ranks #1340 of 457151 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). These extreme national outlier rankings for common E/M codes suggest an above-average outpatient visit volume and/or sustained high-intensity clinic throughput compared with national peers.
The NPI was enumerated on 2007-04-19 (~19 years ago), indicating long tenure in the market; combined with the high infusion and immunotherapy volumes, this tenure is consistent with an established oncology practice and referral network that supports sustained treatment and infusion services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
67 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 20,200 | $40 | $868.6K |
| J9299 | Injection, nivolumab, 1 mg | 32,280 | $20 | $774.7K |
| J0897 | Injection, denosumab, 1 mg | 17,040 | $20 | $306.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,760 | $100 | $167.3K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 7,260 | $20 | $167K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,760 | $70 | $121.3K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,380 | $30 | $114.9K |
| J9312 | Injection, rituximab, 10 mg | 1,780 | $60 | $113.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 900 | $100 | $92.4K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 1,030 | $90 | $88.8K |
Showing 1–10 of 67
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
67 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 21 | 110 | 11,600 | $40 | $564.2K |
| J9299 | 3 | 30 | 9,570 | $20 | $305.2K |
| J9312 | 6 | 10 | 2,000 | $60 | $129.8K |
| Q5118 | 1 | 10 | 4,490 | $20 | $105.3K |
| J1568 | 2 | 10 | 2,190 | $30 | $96.9K |
| J0897 | 18 | 410 | 2,520 | $20 | $90.8K |
| Q5119 | 10 | 40 | 1,970 | $20 | $50.6K |
| Q5122 | 6 | 30 | 410 | $90 | $44.1K |
| J0881 | 16 | 70 | 11,600 | $1 | $38.2K |
| J2506 | 2 | 70 | 320 | $80 | $32.9K |
Showing 1–10 of 67
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,460 | $30 | $37.8K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 940 | $30 | $26.3K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 140 | $20 | $3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 40 | $10 | $190 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,502 | 14,680 | 300 | $50 | $48.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 11,769 | 14,190 | 280 | $20 | $38.9K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 2,219 | 3,830 | 210 | $40 | $29.4K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 1,096 | 4,800 | 210 | $30 | $29.3K |
Other providers in the same ZIP code as Veerpal Singh, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ecker Center For Behavioral Health | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $20M |
| A-tec Ambulance Service Inc | IL | Land Ambulance | $3.4M | $8.3M |
| Kenneth Laferle | IL | Audiologist | $8K | $5.8M |
| Vna Health Care | IL | Federally Qualified Health Center (FQHC) | $0 | $5.1M |
| Cranial Technologies, Inc. | IL | Prosthetic/Orthotic Supplier | $0 | $4M |
| Syed Zahir | IL | Hematology & Oncology Physician | $3.1M | $72.4K |
| Suleman Bangash | IL | Dermatology Physician | $3M | $5.2K |
| Rashmi Kapur | IL | Ophthalmology Physician | $1.6M | $1.1M |
| Rehan Hussain | IL | Ophthalmology Physician | $2.2M | $236K |
| Nexgen Labs Inc | IL | Clinical Medical Laboratory | $204.3K | $2.1M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.